Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986445 | 0.94 | BUB1 (0.75) | BUB1 | |
| SCHEMBL18986573 | 0.91 | BUB1 (0.62) | BUB1 | |
| SCHEMBL18986415 | 0.90 | BUB1 (0.68) | BUB1 | |
| SCHEMBL18987028 | 0.89 | BUB1 (0.68) | BUB1 | |
| SCHEMBL18986908 | 0.89 | BUB1 (0.77) | BUB1 | |
| SCHEMBL18986634 | 0.89 | BUB1 (0.74) | BUB1 | |
| SCHEMBL18986621 | 0.89 | BUB1 (0.73) | BUB1 | |
| SCHEMBL22189865 | 0.85 | BUB1 (0.63) | BUB1 | |
| SCHEMBL18986252 | 0.85 | BUB1 (0.63) | BUB1 | |
| SCHEMBL20233987 | 0.85 | BUB1 (0.84) | BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216439-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-09 | — | — | US | claimed |
| EP-3390401-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | claimed |
| WO-2017102649-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | claimed |
| US-20200216439-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-09 | — | — | US | disclosed |
| US-20200216439-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-09 | — | — | US | disclosed |
| EP-3390401-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102649-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216439-A1 | HETERO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | CYP2D6, CYP1B1, CYP3A4 | BUB1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.